Novogen (ASX:NRT; NASDAQ:NVGN) is an emerging oncology-focused biotech with a portfolio of four development candidates, which have the potential to yield first-in-class and best-in-class agents across a range of oncology indications.
Find out more from Dr James Garner at Proactive's CEO Sessions.
Click on city below to register by email
- Melbourne: Tuesday 11th April.
- Sydney: Wednesday 12th April.
- Email Pauline here.
- Call office on (02) 9280 0700.
Presenter list
- Intermin Resources (ASX:IRC): MD Jon Price
- Southern Gold (ASX:SAU): MD Simon Mitchell
- Proteomics International Laboratories (ASX:PIQ): MD Richard Lipscombe
- Dimerix (ASX:DXB): CEO Kathy Harrison
- Novogen (ASX:NRT, NASDAQ:NVGN): CEO Dr James Garner (presenting in Melbourne only)